Results 141 to 150 of about 259,065 (325)

Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature

open access: yesArrhythmia & Electrophysiology Review, 2020
Roberto Keegan   +2 more
doaj   +1 more source

Idiopathic Submitral Left Ventricular Aneurysm: an Unusual Substrate for Ventricular Tachycardia in Caucasians [PDF]

open access: yes, 2005
Annular submitral aneurysms have been rarely reported in Caucasians. They are typically diagnosed in non-white adults who present with severe mitral regurgitation, heart failure, systemic embolism, ventricular arrhythmias, and sudden cardiac death.
Arash, Arya   +3 more
core  

Short report: Hospitalization for new‐onset heart failure in survivors of hospitalized COVID‐19

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Previous studies have reported an incidence of new‐onset heart failure (HF) among COVID‐19 survivors ranging from 0.7 to 8.5 per 100 person‐years, but they relied on administrative data for outcome ascertainment. Given the public health implications, a more accurate characterization of the HF burden post‐COVID‐19 is important. Methods and
Vicente Corrales‐Medina   +6 more
wiley   +1 more source

Lower left ventricular ejection time in MYBPC3 variant carriers with overt or subclinical hypertrophic cardiomyopathy

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Hypertrophic cardiomyopathy (HCM) is an inherited cardiomyopathy often caused by pathogenic variants in MYBPC3 and MYH7, encoding myosin‐binding protein C3 and myosin heavy chain 7, respectively. These variants can cause increased actin–myosin crossbridge cycling, resulting in ventricular hypercontractility, but mice lacking Mybpc3 ...
Isabell Yan   +10 more
wiley   +1 more source

Heart Failure with Preserved Ejection Fraction and Sudden Death: How to Identify High Risk Patients?

open access: yesJournal of Cardiac Arrhythmias, 2020
Background: Cardiac failure with preserved ejection fraction corresponds to half of the cardiac failure cases, having a similar prognosis to patients with reduced ejection fraction.
Bruno Finkler   +7 more
doaj  

Angiotensin receptor‐neprilysin inhibitors in concurrent heart failure with reduced ejection fraction and kidney failure

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Angiotensin receptor‐neprilysin inhibitor (ARNI) therapy has demonstrated improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, its benefits in patients with concomitant kidney failure undergoing replacement therapy remain uncertain. Methods and results Using the National Health Insurance Service database, we
Mi‐Hyang Jung   +8 more
wiley   +1 more source

Loss of muscleblind-like 1 results in cardiac pathology and persistence of embryonic splice isoforms. [PDF]

open access: yes, 2015
Cardiac dysfunction is a prominent cause of mortality in myotonic dystrophy I (DM1), a disease where expanded CUG repeats bind and disable the muscleblind-like family of splice regulators.
Choi, Jongkyu   +8 more
core  

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. ARNI, angiotensin receptor/neprilysin inhibitor; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; GDMT, guideline‐directed medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection ...
Clara I. Saldarriaga   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy